Longduoduo Co Ltd (LDDD) Longduoduo Company Limited, along with its associated entities, operates within the People's Republic of China, focusing on providing proactive health management and preventative medical services. The company's comprehensive suite of offerings includes health screenings, diverse treatment options, and specialized healthcare products, all aimed at reducing the likelihood of severe conditions such as myocardial infarction (heart attacks), cerebral infarction (strokes), hemiplegia (paralysis), and other cardiovascular and cerebrovascular diseases. These services are delivered through an extensive network of external collaborators, including independent healthcare providers, product vendors, and sales representatives. Additionally, Longduoduo features a range of advanced therapeutic interventions. These encompass meridian-regulating and consciousness-restoring techniques, a double blood purification process, immunological ozonated autohemotherapy, platelet-rich plasma therapy, relaxation techniques, vegetative nerve regulation, and microwave therapy. Established in 2020, the firm's primary operational base is located in Hohhot, China.
Sector: Services-Health Services
Industry: Medical - Diagnostics & Research
Longduoduo Company Limited OTC:LDDD Healthcare · Medical - Diagnostics & Research
All Press Release SEC Filings News
SEC Filing ⚠ 7
LDDD: 10-K · periodic report
Longduoduo's fiscal 2026 revenue collapsed 57% to $1,822,457 from $4,262,663, and the company swung to a net loss of $642,267 versus net income of $492,260 a year earlier.
Nearly all revenue (over 99.6%) now comes from commissions as sales agent for a single counterparty, Inner Mongolia Honghai Health Management, while its legacy principal-sales business shrank by roughly 95%.
The company ended the year with $1,588,930 in cash but only $501,414 of working capital, and management warns it cannot assure it can remain a going concern without additional financing, which it expects partly from majority shareholder Zhang Liang.
The Nevada holding company's entire operations sit in PRC subsidiaries, exposing investors to CSRC approval requirements, HFCAA-related delisting risk, and capital-transfer restrictions; the stock trades thinly on OTCID as LDDD with a non-affiliate float of only about $8.6 million.
SEC 10-K • 26d ago AI analysis › SEC Filing ⚠ 2
LDDD: NT 10-K · late filing
Longduoduo Company Limited filed an NT 10-K on September 28, 2026, notifying the SEC that it could not file its annual report for the fiscal year ended June 30, 2026 on time. The stated reason is a delay in completing the calculations necessary to close the books for the year.
The company expects to file the 10-K on or before the fifteenth calendar day following the prescribed due date under Rule 12b-25. It also stated it does not anticipate a significant change in results of operations versus the prior fiscal year.
Late 10-K filings often signal accounting or internal-control issues, so investors should watch for the eventual annual report and any restatement or auditor disclosures. All prior periodic reports in the preceding 12 months were filed on time, per the notification.
SEC NT 10-K • 28d ago SEC Filing ⚠ 4
LDDD: 8-K · leadership change
Binbin Wu, Jiayang Ma and Bo Shan each resigned from Longduoduo Company Limited's Board of Directors on September 14, 2026, in a simultaneous departure disclosed under Item 5.02 of a Form 8-K filed September 16, 2026.
Each resigning director certified that the decision did not result from any disagreement relating to the registrant's operations, policies or procedures, and the filing announces no replacement directors.
The mass exit thins board oversight at the Nevada-incorporated, Inner Mongolia-based issuer and is likely to draw governance scrutiny, even though CEO Zhou Hongxiao remains in place.
SEC 8-K • 1mo ago AI analysis › SEC Filing ⚠ 7
LDDD: 10-Q · periodic report
Longduoduo Company Limited reported a significant deterioration in financial performance for the nine months ended March 31, 2026, swinging from a net income of $325,775 in the prior year to a net loss of $575,434. Total revenue plummeted 64% year-over-year to $1.19 million, driven by a 76% decline in commission revenue as the company cited a weak economic environment and cautious consumer spending in China.
Management disclosed material weaknesses in internal controls over financial reporting, noting the small accounting staff lacks expertise in U.S. GAAP and the CFO is unfamiliar with public company reporting requirements. Additionally, the company reported negative operating cash flow of $437,881 for the period, despite holding $1.22 million in cash, largely due to the use of customer prepayments to fund ongoing operations.
The company acknowledged substantial uncertainty regarding its ability to continue as a going concern, stating it cannot provide assurances it will generate sufficient cash flows or obtain financing to remain viable. Operations remain highly concentrated, with one customer accounting for 99.1% of revenue for the nine-month period, and the company continues to rely on support from its majority shareholder, Zhang Liang.
SEC 10-Q • 5mo ago AI analysis › Recent SEC filings with analysis